Search

Your search keyword '"Rodolfo, Monica"' showing total 6 results
Start Over Author "Rodolfo, Monica" Journal cancer research
6 results on '"Rodolfo, Monica"'

2. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma

Author

Patel, Ankit, primary, Garcia, Lucia Fraile, additional, Mannella, Viviana, additional, Gammon, Luke, additional, Borg, Tiffanie-Marie, additional, Maffucci, Tania, additional, Scatolini, Maria, additional, Chiorino, Giovanna, additional, Vergani, Elisabetta, additional, Rodolfo, Monica, additional, Maurichi, Andrea, additional, Posch, Christian, additional, Matin, Rubeta N., additional, Harwood, Catherine A., additional, and Bergamaschi, Daniele, additional

Published
2020
Full Text
View/download PDF

3. Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, additional, Camisaschi, Chiara, additional, Deho, Paola, additional, Cabras, Antonello D., additional, Sensi, Marialuisa, additional, De Cecco, Loris, additional, Bassani, Niccolò, additional, Ambrogi, Federico, additional, Carbone, Antonino, additional, Crippa, Federica, additional, Vergani, Barbara, additional, Frati, Paola, additional, Arienti, Flavio, additional, Patuzzo, Roberto, additional, Villa, Antonello, additional, Biganzoli, Elia, additional, Canevari, Silvana, additional, Santinami, Mario, additional, Castelli, Chiara, additional, Rivoltini, Licia, additional, and Rodolfo, Monica, additional

Published
2014
Full Text
View/download PDF

4. CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma

Author

Vallacchi, Viviana, primary, Daniotti, Maria, additional, Ratti, Francesca, additional, Di Stasi, Delia, additional, Deho, Paola, additional, De Filippo, Annamaria, additional, Tragni, Gabrina, additional, Balsari, Andrea, additional, Carbone, Antonino, additional, Rivoltini, Licia, additional, Parmiani, Giorgio, additional, Lazar, Noureddine, additional, Perbal, Bernard, additional, and Rodolfo, Monica, additional

Published
2008
Full Text
View/download PDF

6. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.

Author

Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, and Castelli C

Subjects
Cell Line, Tumor, HLA-A2 Antigen immunology, Humans, Immunoglobulin G biosynthesis, Immunoglobulin G blood, Immunohistochemistry, Lymphocyte Activation immunology, Peptide Fragments immunology, Protein Biosynthesis, Proteins genetics, Reverse Transcriptase Polymerase Chain Reaction, Antigens, Neoplasm, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Epitopes, T-Lymphocyte immunology, Membrane Proteins, Neuroblastoma immunology, Proteins immunology, T-Lymphocytes immunology
Abstract

Neuroblastoma cells have been shown to express molecularly defined tumor-associated antigens, which could represent potential targets of T and/or B cell-mediated immunity. However, the existence of a spontaneous immune response to such tumor antigens in neuroblastoma patients has yet to be investigated. In the present work we addressed the issue of whether NY-ESO-1, a germ cell antigen aberrantly expressed in different tumor types, is expressed by neuroblastoma cells and may represent a target for humoral and/or cellular immune responses in neuroblastoma patients. We found that a large fraction of neuroblastoma biopsies, independently from the clinical stage and degree of tumor cell differentiation, expressed significant levels of NY-ESO-1 as assessed by reverse transcription-PCR and immunohistochemistry. NY-ESO-1-specific IgG antibodies were detected in the sera of 10% of neuroblastoma patients with stage III or IV disease, but not in patients in clinical remission or with earlier stages. This suggests that antibody production occurred as a late event in the course of disease. NY-ESO-1-specific immune responses were observed for CD4(+) and CD8(+) T cells from peripheral blood lymphocytes in 4 of 8 neuroblastoma patients, as detected by IFN-gamma enzyme-linked immunospot assay after in vitro stimulation either with the NY-ESO-1 recombinant protein or with the HLA-A2-restricted peptide NY-ESO-1(157-167). NY-ESO-1-specific CD4(+) and CD8(+) T cells were also able to recognize NY-ESO-1 expressing neuroblastoma cells. The presence of T cells specific for NY-ESO-1 antigen was not associated with the stage of disease, or to the presence or absence of NY-ESO-1 specific antibodies. We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results